HCW BIOLOGICS INC (HCWB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.04-3.70%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · HCWB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -82.3% |
| Our one-year growth estimate | diamond | 100.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 182.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
HCWB — capital allocation — Unregistered Sales of Equity Securities
Dated 2026-09-24
Unregistered Sales of Equity Securities. The issuance and sale of the Shares and the Pre-Funded Warrants at the closing were made, and the issuance of the Warrant Shares upon exercise of the Pre-Funded Warrants and the Common Warrants will be made, in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation D promulgated thereunder, as transactions by an issuer not involving a publ…
Why it matters: The planned cancer trial depends on FDA authorization. A start in the first half of 2027 would show the program cleared this step.
Watch forThe FDA authorizes the HCW11-018b study, and the company starts enrollment by June 30, 2027.
Also watch forThe FDA does not authorize the study, or enrollment has not started by June 30, 2027.
Why it matters: The audit committee said investors should no longer rely on the March statements. Corrected results can clarify cash and reported income.
Watch forHCW Biologics files corrected March 2026 statements. It explains changes to revenue, cash, and net income.
Also watch forThe company does not file corrected statements, or the filing shows more errors in those results.
Why it matters: The first three patients at 3 micrograms/kg had better SALT scores. The full readout can test whether that early change holds.
Watch forThe Q4 2026 readout shows SALT scores improve in more than three patients in cohort two. It reports no dose-limiting toxicities.
Also watch forThe results show no SALT improvement in any group, or report toxicities that limit the dose.
Why it matters: The company has raised money through several stock deals. Its earlier filing said it needed more funds to keep operating for 12 months.
Worry ifThe November 13 report says cash is below $1.2 million, or says more funding is needed to keep operating.
Less concerning ifThe report shows at least $1.2 million in cash and says available funds cover operations for the next 12 months.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$434 on $10,000 · ±4.3% | How much price usually moves either way. |
| Bad day | $1,614 loss on $10,000 · 16.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,471 loss on $10,000 · 94.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.